RE:RE:Anacetrapib - another CETP still killing people?I'm not sure abou the half-life of the torcetrapib or dalcetrapib, but here is a pargraph from ( https://www.ncbi.nlm.nih.gov/pubmed/24786356) that talks about the half-life of anacetrapib and evacetrapib:
"The present study also showed that almost complete washout of evacetrapib occurred within the 4- to 6-week reversal period after 12 weeks of evacetrapib monotherapy as well as in combination with atorvastatin. The effects on lipids (HDL-C and LDL-C) and CETP mass and activity were no longer apparent after 4 to 6 weeks of drug cessation, consistent with evacetrapib blood levels that were near or below the quantitation limit of the assay. These observations are consistent with the terminal half-life of evacetrapib.16 In contrast, persistent plasma anacetrapib concentrations and significant lipid changes (LDL-C and HDL-C) were observed 8 weeks after the last dose of anacetrapib (given for 8 weeks at 100 or 300 mg/day dose).3 Approximately 20% of the plasma anacetrapib concentrations remained at each anacetrapib dose as monotherapy or in coadministration with atorvastatin. Approximately 1/3 to 1/2 of the effect on LDL-C and approximately 1/5 to 1/2 of the effect on HDL-C with anacetrapib at week 8 were still observed 8 weeks after anacetrapib cessation. Moreover, Gotto et al2 have also recently shown that significant concentrations of anacetrapib are still measurable in plasma 12 weeks after cessation of treatment in the 76-week DEFINE study, strongly suggesting that evacetrapib and anacetrapib differ in the way they are distributed and/or eliminated."